Oppenheimer Initiates Coverage On Abbott Laboratories With Outperform Rating, Announces Price Target of $130
Oppenheimer Initiates Coverage On Abbott Laboratories With Outperform Rating, Announces Price Target of $130
Oppenheimer開始覆蓋雅培，評級爲跑贏市場，宣佈目標股價爲130美元。
Oppenheimer analyst Suraj Kalia initiates coverage on Abbott Laboratories (NYSE:ABT) with a Outperform rating and announces Price Target of $130.
Oppenheimer分析師Suraj Kalia開始覆蓋雅培實驗室（紐交所:ABT），評級爲Outperform，並宣佈價格目標爲130美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。